Guy Goodwin

Last updated

Guy Manning Goodwin
Born (1947-11-08) 8 November 1947 (age 76)
EducationB.A. in Animal Physiology, DPhil in Neurophysiology, University of Oxford
Known forNeurobiology of bipolar disorder, neuroscience of mood disorders and brain structure/function imaging
AwardsMogens Schou Award for Research, NHS Live Innovation award
Scientific career
Fields Psychiatry
Institutions University of Oxford, Department of Psychiatry (Medical Sciences Division)

Guy Goodwin is a senior research fellow and until recently was the W.A. Handley Professor of Psychiatry at the University of Oxford (2014). [1] A fellow of the Academy of Medical Sciences, Goodwin has served as principal investigator in many clinical trials for the treatment of bipolar disorder. He is also an Emeritus Senior Investigator at the National Institute for Health and Care Research (NIHR) [2] and has been on the advisory boards of numerous research councils. He was President of the European College of Neuropsychopharmacology from 2013 to 2016. [3]

Contents

Career

Research focus/interests

Goodwin's research focuses on the neurobiology of mood disorders, notably bipolar disorder and its treatment. In addition to developing novel treatments for mood disorders, Goodwin is interested in the impact of treatments on both the physiological and psychological levels, using brain imaging techniques to study the effects of treatment on brain structure and function as well as the connection between depression and memory impairment.

Notable contributions to research

Goodwin's findings on the impact of depression on brain tissue and memory have led to greater interest in neurogenesis when developing antidepressants as well as the role of cognition in the treatment of depression. [1]

Goodwin was the principal investigator of many clinical trials for treatments of bipolar affective disorder, including the BALANCE, CEQUEL, and OXTEXT studies. [1] He serves on the advisory boards of many biopharmaceutical companies including AstraZeneca and Pfizer.

Past appointments

After completing his DPhil in Neurophysiology at Oxford, Goodwin qualified in psychiatry and went on to become a Clinical Scientist and Consultant Psychiatrist in the MRC Brain Metabolism Unit at the University of Edinburgh for 10 years. He then returned to Oxford as Professor of Psychiatry. [4]

Professor Goodwin has been the head of Oxford University's Department of Psychiatry since 2006, and a fellow of Merton College, Oxford since 1996. [5]

Awards

Goodwin has won numerous awards, most recently the Mogens Schou Award for Research (2009) [6] and the NHS Live Innovation Award with Professor John Geddes for developing the True Colours system that allowed them to remotely monitor the symptoms of their bipolar patients. [7]

Positions of trust and research assessments

Dr. Goodwin is currently President of the European College of Neuropsychopharmacology (2013–16). [8] From 1997 to 2007, he was the non-executive Director and Vice-Chair of the Oxfordshire and Buckinghamshire NHS Mental Health Trust Board.

Goodwin has served on numerous advisory boards including the Evaluation committee for neuroscience, neurology, and psychiatry of the Agence Nationale de Recherche, France, the Wellcome Trust Neurosciences Panel, the Council of the British Association for Psychopharmacology, and Medical Research Council's Clinical fellowships panel and Advisory Board. He was elected president of the British Association for Psychopharmacology in 2004–05. [9]

Publications

Goodwin has published extensively, authoring a book on bipolar disorder as well as numerous articles. He also regularly reviews books in the field. [10]

Related Research Articles

The emphasis of the treatment of bipolar disorder is on effective management of the long-term course of the illness, which can involve treatment of emergent symptoms. Treatment methods include pharmacological and psychological techniques.

Mogens Schou was a Danish psychiatrist whose research into lithium led to its utilization as a treatment for bipolar disorder.

Alec James Coppen was a British psychiatrist. He was given The Pioneers in Psychopharmacology Award in year 2000 by the Collegium Internationale Neuro Psychopharmacologicum.

Frederick King Goodwin was an American psychiatrist and Clinical Professor of Psychiatry at the George Washington University Medical Center, where he was also director of the Center on Neuroscience, Medical Progress, and Society. He was a specialist in bipolar disorder and recurrent depression.

<span class="mw-page-title-main">Dennis S. Charney</span> American medical researcher

Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

Jules Angst is a Swiss academic who is Emeritus Professor of Psychiatry at Zurich University in Zurich, Switzerland, and Honorary Doctor of Heidelberg University in Heidelberg, Germany.

Barbara Jacquelyn Sahakian, is professor of clinical neuropsychology at the department of psychiatry and Medical Research Council (MRC)/Wellcome Trust Behavioural and Clinical Neuroscience Institute, University of Cambridge. She is also an honorary clinical psychologist at Addenbrooke's Hospital, Cambridge. She has an international reputation in the fields of cognitive psychopharmacology, neuroethics, neuropsychology, neuropsychiatry and neuroimaging.

Ronald Robert Fieve was an American psychiatrist known for his work on the use of lithium in treatment of mood disorders. He has authored four popular science books, "Moodswing", "Bipolar II", "Prozac" and "Bipolar Breakthrough".

<span class="mw-page-title-main">Eduard Vieta</span> Spanish psychiatrist (born 1963)

Eduard Vieta Pascual is a Spanish psychiatrist and a leading scientific authority on the neurobiology and treatment of bipolar disorder.

Mark J. Millan is a neuroscientist specialising in the study and improved treatment of disorders of brain. He was the Director of Pharmacological Innovation for the Central Nervous System (CNS) at the Institut de Recherché de Servier (IDRS) in Paris, France. He is also the Secretary of the European College of Neuropsychopharmacology. Currently he is a Visiting Professor in the School of Psychology and Neuroscience at the University of Glasgow. Born in Edinburgh, he is the son of former Scottish Labour Party Leader and European Commissioner, Bruce Millan. He studied at Cambridge University and then spent ten years at the Max Planck Institute of Psychiatry, Munich, before moving to Paris.

Wim van den Brink is emeritus Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam. He was Director of the Amsterdam Institute for Addiction Research (AIAR) and Scientific Director of the National Committee for Treatment of Heroin Addiction (CCBH) in Utrecht, the Netherlands.

Martien J.H. Kas is associate professor in the Department of Translational Neuroscience, Brain Center Rudolf Magnus, at the University Medical Center Utrecht, where he leads a work group entitled "Translational Behavioral Genetics" that researches cross-species behavioral genetics to better understand origins and develop treatments for psychiatric disorders.

Joseph Zohar is the director of Psychiatry and the Anxiety and Obsessive Compulsive Clinic at the Sheba Medical Center in Tel HaShomer and professor of psychiatry at Tel Aviv University, Israel. He is the founder of the World Council on Anxiety as well as the Israeli Consortium on PTSD. He currently leads the chief installation of the Israeli Defense Force for the treatment of PTSD. He is a member of the executive committee of the European College of Neuropsychopharmacology, of which he is a former president, and chairman of the Expert Platform on Mental Health.

<span class="mw-page-title-main">Stephen Stahl</span> American psychiatrist

Stephen Michael Stahl is an author and professor of psychiatry with expertise in psychopharmacology. He is currently a professor at the University of California, San Diego, and serves as Honorary Fellow in psychiatry department at the University of Cambridge. He is also the chairman of Neuroscience Education Institute (NEI) and Arbor Scientia Group.

Hilary Patricia Blumberg is a medical doctor and the inaugural John and Hope Furth Professor of Psychiatry at the Yale School of Medicine. She is also a professor of Radiology and Biomedical Imaging, and works in the Child Study Center at Yale where she has been a faculty member since 1998. She attended Harvard University as an undergraduate, and completed medical school at Cornell University Medical College (1990). She completed her medical internship and psychiatry residency at Cornell University Medical College/New York Hospital, and her neuroimaging fellowship training at Cornell University, Weill Medical College. She has received the 2006 National Alliance for Research in Schizophrenia and Depression (NARSAD) and the Gerald L. Klerman Award for Clinical Research. Blumberg has authored a number of scientific articles that focus on bipolar disorder, neuroimaging, and effects of specific genetic variations, developmental trajectories and structure-function relationships.

Hans-Ulrich Wittchen is a clinical psychologist, psychotherapist and epidemiologist. He has been a head of the Institute of Clinical Psychology and Psychotherapy and the Center of Clinical Epidemiology and Longitudinal Studies (CELOS) at the Technische Universität Dresden. Since 2018, he is leading the research group "Clinical Psychology and Psychotherapy Research" at the Psychiatric Clinic of Ludwig-Maximilians-Universität München and directs the IAP-TU Dresden GmbH in Dresden.

Stan Kutcher is a Canadian Senator and Professor Emeritus of Psychiatry at Dalhousie University. He was appointed to the Senate of Canada on 12 December 2018.

<span class="mw-page-title-main">Haim Belmaker</span> Israeli professor of psychiatry

Prof. Robert Haim Belmaker, is an Israeli psychiatrist who has had major academic positions in Israeli psychiatry since 1974. He had a formative influence on biological directions in Israeli psychiatry. He was Hoffer-Vickar Professor of Psychiatry at Ben-Gurion University of the Negev, Beersheva Israel until his retirement and is now Emeritus.

René Sylvain Kahn is a neuropsychiatrist and the Esther and Joseph Klingenstein Professor and System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai in the United States, a position he has held since 2017. He previously served as Professor of Psychiatry and Director of the Brain Center Rudolf Magnus at the University Medical Center Utrecht in the Netherlands. Kahn is recognized for his research on the neurobiology of schizophrenia. He served as a former president of the Schizophrenia International Research Society and was elected to the Royal Netherlands Academy of Arts and Sciences in 2009. He received the Neuropsychopharmacology Award from the European College of Neuropsychopharmacology in 2014.

Mauricio Tohen is a Mexican American research psychiatrist, Distinguished Professor, and Chairman of the Department of Psychiatry & Behavioral Sciences at the University of New Mexico. Tohen's research has focused on the epidemiology, outcome, and treatment of bipolar and psychotic disorders, and is especially known for innovating the design of clinical trials and the criteria to determine outcome in such diseases. Tohen has edited several books on his specialties. His social awareness has been noted in the promotion of programs to improve mental health care in areas such as substance abuse, bipolar disorder and schizophrenia.

References

  1. 1 2 3 "Guy Goodwin". University of Oxford. Retrieved 6 July 2015.
  2. ↑ "Guy Goodwin". www.psych.ox.ac.uk. Retrieved 13 February 2022.
  3. ↑ "Past ECNP Presidents". The European College of Neuropsychopharmacology. Retrieved 9 February 2021.
  4. ↑ "Guy Goodwin, MD, WA Handley Professor of Psychiatry, University of Oxford". gmeded.com. Retrieved 6 July 2015.
  5. ↑ "Professor Guy Goodwin". University of Oxford. Retrieved 6 July 2015.
  6. ↑ "Mogens Schou Awards". isbd.org. Archived from the original on 7 July 2015. Retrieved 6 July 2015.
  7. ↑ "'Modernisation' is not a dirty word". hsj.co.uk. 10 September 2013. Archived from the original on 6 July 2015. Retrieved 6 July 2015.
  8. ↑ "The Executive Committee". ecnp.eu. Archived from the original on 6 July 2015. Retrieved 6 July 2015.
  9. ↑ "Professor Guy Goodwin". bjhim-online.org. Archived from the original on 6 July 2015. Retrieved 6 July 2015.
  10. ↑ "Guy M. Goodwin". academic.research.microsoft.com/. Retrieved 6 July 2015.[ permanent dead link ]
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.